The Latest Breaking News from Vaccine

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK · Sep 2, 2022

EU regulator gives green light to omicron booster vaccines

The European Medicines Agency (EMA) has backed two separate Covid-19 booster vaccines updated to target the omicron variant of Covid-19 and developed by drugmakers Moderna and BioNTech-Pfizer.

Radio France Internationale · Sep 2, 2022

New omicron COVID-19 boosters are coming. Here’s what you need to know

DENVER — COVID-19 booster shots with a new omicron-targeting recipe are expected to arrive in pharmacies and clinics next week, but the experience of getting them will be largely the same as previous rounds of the vaccine.

The Denver Post · Sep 2, 2022

Nine Omicron symptoms affecting the fully vaccinated - and signs you may have it

Fainting and fatigue may signal onset of variant, experts say

The Independent UK · Sep 2, 2022

Novak Djokovic’s absence from the US Open has made him a hero to the right

The three-time champion at Flushing Meadows is forbidden from entering the US. Many conservatives have used him to push their agenda

The Guardian - US · Sep 2, 2022

CDC recommends updated COVID-19 boosters

The CDC recommends the new Pfizer-BioNTech booster for individuals 12 years and the Moderna vaccine for individuals 18 and up.

Axios · Sep 1, 2022

CDC advisers endorse booster shots that target omicron for Americans 12 and up

The United States should replace most of its COVID-19 booster shots with updated versions that target the dominant omicron strains, an influential group of vaccine experts that advises the Centers for Disease Control and Prevention said Thursday.

Los Angeles Times · Sep 1, 2022

CDC advisers back use of updated COVID-19 vaccine boosters - Roll Call

Moderna’s shot will be available to adults 18 and older, and Pfizer’s will be available to individuals 12 and older.

Roll Call · Sep 1, 2022

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

Benzinga · Sep 1, 2022

CDC recommends new booster shots to fight omicron

CDC Director Rochelle Walensky has signed off on updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.

WEKU · Sep 1, 2022